Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease by Sookoian, Silvia Cristina & Pirola, Carlos José
Systematic review with meta-analysis: the significance of
histological disease severity in lean patients with nonalcoholic
fatty liver disease
S. Sookoian1,2 | C. J. Pirola1,3
1Institute of Medical Research A. Lanari,
University of Buenos Aires, Buenos Aires,
Argentina
2Department of Clinical and Molecular
Hepatology, Institute of Medical Research
(IDIM), National Scientific and Technical
Research Council (CONICET)-University of
Buenos Aires, Buenos Aires, Argentina
3Department of Molecular Genetics and
Biology of Complex Diseases, Institute of
Medical Research (IDIM), National
Scientific and Technical Research Council
(CONICET)-University of Buenos Aires,
Buenos Aires, Argentina
Correspondence
Dr. S Sookoian and Dr. CJ Pirola, Instituto
de Investigaciones Medicas, IDIM-CONICET,
Argentina.
Emails: sookoian.silvia@lanari.fmed.uba.ar;
pirola.carlos@lanari.fmed.uba.ar
Funding information
Fondo para la Investigacion Cientıfica y
Tecnologica, Grant/Award Number: PICT
2014-0432, PICT 2014-1816, PICT 2015-
0551
Summary
Background: Current evidence suggests that lean and obese patients with nonalco-
holic fatty liver disease (NAFLD) share an altered metabolic and cardiovascular
profile. However, there is an incomplete understanding of the natural history of
“lean-NAFLD.” Indeed, an unanswered question is whether lean (BMI ≤ 25 Kg/m2)
NAFLD-patients are protected from severe histological outcomes.
Aim: To perform a meta-analysis with the goal of providing a quantitative estima-
tion of the magnitude of fibrosis, as well as histological features associated with the
disease severity, in lean versus overweight/obese-NAFLD patients.
Methods: Through a systematic search up to July 2017, we identified eight studies
that compared histological outcomes in lean (n = 493) versus overweight/obese
(n = 2209) patients.
Results: Relative to lean-NAFLD, overweight/obese-NAFLD patients showed signifi-
cantly (P = .032) higher fibrosis scores; the observed difference in means between
the two groups, which is the absolute difference between the mean value of fibrosis
score [0-4]  standard error, was 0.28  0.13. The risk of having nonalcoholic
steatohepatitis-NASH (OR 0.58 95% CI 0.34-0.97) was significantly lower in lean-
NAFLD (n = 322) than in overweight/obese-NAFLD (n = 1357), P = .04. Relative to
lean-NAFLD, overweight/obese-NAFLD patients also have significantly greater
NAFLD activity (difference in means  SE: 0.58  0.16, P = .0004) and steatosis
(difference in means  SE: 0.23  0.07, P = .002) scores.
Conclusions: Lean-NAFLD patients tend to show less severe histological features as
compared to overweight/obese-NAFLD patients. Subsequent longitudinal assess-
ment is needed to understand the clinical impact of these findings; however, the
significant ~ 25% increment of mean fibrosis score in overweight/obese patients
suggests that obesity could predict a worse long-term prognosis.
As part of AP&T’s peer-review process, a technical check of this meta-analysis was per-
formed by Dr. Y. Yuan. The Handling Editor for this article was Prof. Stephen Harrison, and
it was accepted for publication after full peer-review.
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1 | INTRODUCTION
The prevalence of nonalcoholic fatty liver disease (NAFLD) has
increased globally,1 paralleling the figures of obesity and type 2 dia-
betes.2,3 These three clinical conditions, also referred to as comor-
bidities, cluster together in the metabolic syndrome (MetS) along
with cardiovascular disease (CVD).4 Nevertheless, obesity constitutes
a key determinant of awareness of liver disease due to the known
risk-adverse association between obesity and NAFLD; both diseases
reflect common—environmental—risk factors, including diet and life-
style.1 However, NAFLD can also occur in lean (nonobese) people;5-7
the term “lean-NAFLD” is commonly used to describe this associa-
tion.
The growing prevalence of NAFLD in Asia has contributed, in
part, to the recognition of lean-NAFLD due to around 8%-19% of
Asians with body mass index (BMI) less than 25 kg/m2 have also
been found to have NAFLD.8 It is now clear, however, that lean-
NAFLD also exists in western countries, as demonstrated in the
results of the national health and nutrition examination survey III
(NHANES III) that showed a prevalence of ~ 7% of lean-NAFLD in
the United States population.9
Unfortunately, being slim (nonobese) does not necessarily
mean one is healthy; in fact, being lean does not always lead to
a lower risk of diabetes,10 CVD,11 or even NAFLD, as recently
suggested.5,12 In a large recent meta-analysis, we demonstrated
that lean and obese patients with NAFLD share a common
altered metabolic and cardiovascular profile.5 Our observations,
indeed, uncovered that lean-NAFLD patients are not necessarily
“healthy lean,” or “free of fat” because relative to lean-non-
NAFLD people, lean-NAFLD individuals showed an excess of
abdominal adipose tissue, probably as the leading cause of their
NAFLD.5
Nevertheless, while the risk factors of NAFLD in lean
patients have been partially clarified,5 knowledge of the natural
history of “lean-NAFLD” is not only poorly understood, but also
remains controversial. In addition, the question of whether non-
obese patients are protected from severe histological outcomes
has not been completely elucidated. It is plausible to speculate
that co-existing diseases, such as obesity and NAFLD, are prone
to worsening the prognosis. However, it has not been estab-
lished whether the presence of one or several of the above-
mentioned comorbidities contributes to NAFLD disease severity,
including fibrosis. The purpose of the present meta-analysis was
to provide a quantitative estimation of the magnitude of fibrosis,
as well as histological features associated with the disease
severity, in lean-NAFLD versus overweight/obese-NAFLD
patients.
2 | METHODS
We followed the appropriate methods for conducting a
meta-analysis of observational studies (MOOSE)13 (Table S1).
2.1 | Search strategy
We searched for published studies on MEDLINE (via-PubMed),
Google Scholar, and The Cochrane Library, including The Cochrane
Central Register of Controlled Trials, using the following keywords
and terms in the title or abstract: “lean nonalcoholic fatty liver dis-
ease” and “nonobese nonalcoholic fatty liver disease;” details on
the Boolean search are disclosed in the Supplementary Material
section. In addition, we checked the reference section of all
retrieved articles for additional literature sources, and the PubMed
link “related articles” was used to identify potentially relevant
papers. The literature search included all studies published before
July 2017 and we imposed no country restrictions. The authors
reviewed all abstracts independently to determine the alignment
with the eligibility criteria, or to establish the appropriateness of
the research topic. If these criteria were met, the authors retrieved
the article and reviewed it in its entirety. There were no discrepan-
cies in this process; details on data search/collection are sum-
marised in Figure S1.
2.2 | Inclusion and exclusion criteria and data
collection
The following inclusion criteria were considered when assessing the
eligibility of the identified studies:
1. Observational studies (cross-sectional or longitudinal studies of
which baseline data was retrieved) that included patients with a
histologically confirmed diagnosis of NAFLD, in which compar-
isons between lean and overweight/obese patients were per-
formed.
2. A clear definition of lean and non-lean (overweight / obese)
patients with NAFLD, expressed as a BMI cut-off, which allows
for the identification of two groups of patients: lean patients
with NAFLD, defined as patients with a BMI ≤ 25 versus non-
lean (overweight / obese) patients with NAFLD, defined as
patients with BMI > 25.
3. A clear exclusion of co-existing common chronic liver diseases
and secondary causes of steatosis, including heavy alcohol con-
sumption, total parenteral nutrition, hepatitis B and C virus infec-
tion, and the use of drugs known to precipitate steatosis.
For each study, we retrieved the following information for inclu-
sion in the meta-analysis: (1) histological features: fibrosis score, pro-
portion of patients with NASH/ non-NASH in each group (lean and
overweight/obese), NAFLD Activity Score (NAS) and steatosis score;
(2) demographic features (age, sex, country of origin as proxy of eth-
nicity); (3) study design and (4) anthropometric variables (waist cir-
cumference) and homoeostatic model assessment-insulin resistance
(HOMA-IR)—whenever available. All quantitative variables had to be
expressed as mean  standard deviation (SD); prior to the analysis,
we converted the standard error (SE) or interquartile range to SD,
whereas the median was converted to mean.
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The following exclusion criteria were also considered when
assessing the eligibility of the identified studies: (1) Studies pertain-
ing to patients with NAFLD in which the authors failed to specify
the BMI categories utilised, as explained above (lean vs non-lean); (2)
duplicate publications; (3) unpublished papers (only full-text journal
articles were included) and (4) papers that included data on NAFLD
patients using a non-standard definition of lean subjects.
2.3 | Statistical analysis
A random effect model was adopted when summarising statistical
synthesis. This model assumes that the treatment effect is not the
same across all studies included in the analysis.
To specifically provide measures of the absolute difference
between the mean values of the explored histological variables (fi-
brosis score F0-F4, NAFLD Activity Score, and steatosis score 0-3)
calculated for two groups (lean vs overweight/obese) we used the
difference in means. This approach was justified, as we used out-
come measurements on the same scale/unit performed by the same
method as described below.14 For the dichotomous variable
(NASH / non-NASH), the effect denotes odds ratio (OR) and corre-
sponding 95% confidence interval (CI).
For each analysis, we generated a forest plot to display results;
as we hypothesised that ethnicity may provide an important source
of variability, we also stratified the estimate of the average effect of
the studies by ethnicity. Details regarding subgroup analyses, meta-
regression and heterogeneity are fully disclosed in the Supporting
information. We performed all calculations using the Comprehensive
Meta-Analysis computer program (BIOSTAT, Englewood, NJ, USA).
2.4 | Assessment of study quality
The quality of the studies included in the meta-analysis was assessed
using The Newcastle-Ottawa Scale (NOS) (see Table S2).
3 | RESULTS
3.1 | Study selection
We retrieved 33 studies that were initially identified using the
search strategy described in Figure S1 as potentially relevant for the
present investigation. We subsequently excluded 25 studies because
they did not meet the inclusion criteria: (1) in two cases, the authors
used a non-conventional definition of a lean individual based on a
non-standard BMI cut-off value (BMI < 30),6,15 and (2) 23 studies
were population-based reports in which NAFLD was diagnosed non-
invasively by imaging techniques or laboratory data, as we previously
explained.5
3.2 | Study characteristics
Thus, we included the remaining eight hospital-based studies that
met the inclusion criteria,5,16-22 including a total of 2702 adult-
patients of both sexes with NAFLD, in the present meta-analysis.
One study belongs to our population that took part in an earlier
lean-NAFLD meta-analysis on epidemiological risk factors.5
We obtained scores of liver fibrosis from one study through con-
tact with the study authors, who generously provided details to cal-
culate the pooled effect.18
Four studies were based on a Caucasian population,5,16,18,22
whereas the remaining four included an Asian population.17,19-21 All
the studies scored well in terms of the selection criteria, comparabil-
ity of lean and overweight/obese NAFLD on the basis of the study
design or analysis, and ascertainment of exposure (see Table S2); in
all the studies, the setting was hospital-based.
There was no apparent selection bias in the indication of liver
biopsy in lean or overweight/obese patients with NAFLD (Table 1);
in all the studies, histological assessment was uniformly performed
according to the NASH clinical research network system developed
by Kleiner et al14 The overall study characteristics, including histo-
logical variables are shown in Table 1.
3.3 | Histological disease severity in lean versus
overweight / obese NAFLD: Being overweight /
obese can raise the risk of NASH and is associated
with a significant increase of the fibrosis score
The analysis of liver fibrosis, which was performed based on pooled
data extracted from eight studies,5,16-19,21,22 showed that over-
weight/obese patients (n = 2209) with NAFLD have significantly
greater fibrosis scores than lean patients (n = 493) (P = .032, see
Figure 1). Specifically, the observed difference in means between
the two groups was 0.28  0.13, which represents an increment
of ~24.82% (over pooled mean fibrosis score of 1.128 in the lean
group) in the mean of fibrosis score in overweight/obese-NAFLD
patients relative to the mean of fibrosis score found in
lean-NAFLD. Egger’s regression intercept confirmed absence of
publication bias (intercept 0.34, P = .83). However, we found
substantial heterogeneity (I2: 73.5, P = .0001) in the analysis of
combined studies.
The estimate of the effect stratified by ethnicity (Asian vs Cau-
casian) is shown in Figure S2; the analysis suggests that the differ-
ence in the fibrosis score between lean and non-lean patients
remained significant among Caucasians. Sub-group analysis showed
that intra-group effect was homogeneous (Asian: I2: 58, P = .068
and Caucasian I2: 55, P = .083).
Although we found that the effect estimate varied among studies
and the observed pooled point estimate of the difference in means
ranged from 0.15 to 0.31, significant results remained after excluding
one study at a time (see Figure S3).
We further explored the potential effect of covariate/s that
could explain the observed difference in the fibrosis score between
lean and overweight/obese patients. Meta-regression analysis did
not reveal any significant correlation between differences in age
(slope: 0.03, P = .27), HOMA-IR (slope: 0.3, P = .09), or waist cir-
cumference (slope: 0.09, P = .49) and liver fibrosis. Nevertheless, the
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TABLE 1 Histological features of patients included in the meta-analysis: lean versus non-lean (overweight/ obese)
Author,
Country
Sample
size (lean/
overweight/
obese)
Indication of liver
biopsy
NASH/
no-NASH
lean (n)
NASH/
no-NASH
obese (n)
Fibrosis score (mean  SD)
NAFLD activity score (NAS)
(mean  SD)
Lean Obese Lean Obese
Akyuz,16
Turkey
37/446 Unclear, retrospective
analysis.
‐ ‐ 0.33  0.74 1  1.48 4.67  3.7 5  1.48
Alam,17
India
56/164 Abnormal liver
enzymes.
30/26 77/87 1.2  0.8 1.1  0.8 4.4  1.4 4.4  1.1
Kumar,20
India
18/73 Unclear, lack of
details.
5/13 36/37 1.52  1.0 2  1 3.3  1.5 4.1  1.4
Fracanzani,18
Italy
143/526 Abnormal liver
enzymes and /or
additional risk factors,
including IR
25/118 215/311 0.7  0.95 1.43  1.17 2.7  1.6 3.9  1.7
Honda,19
Japan
134/406 Evaluation of NAFLD
severity
‐ ‐ 1.6  1.1 1.7  1.0 3.5  1.6 4.2  1.5
Leung,21
Hong Kong
72/235 Abnormal liver enzymes,
evaluation of NAFLD
severity, enrolment in
clinical trials.
30/42 121/114 1.3  1.5 1.7  1.4 3.3  1.3 3.8  1.2
Margariti,22
Grece
8/48 Patients who consented
to the biopsy.
4/4 33/15 1.5  1.7 1.5  1.2 3.1  1.9 4.0  1.9
Sookoian,5
Argentina
25/311 Abnormal liver enzymes
and /or additional
risk factors, including IR.
12/13 181/130 0.6  0.96 0.87  1.22 3.37  1.99 3.71  1.41
The presence of NASH, fibrosis and NAFLD activity score (NAS), were assessed in all the studies according to the NASH clinical research network sys-
tem developed by Kleiner et al.14
Lean vs overweight/obese patients with NAFLD: Liver Fibrosis
Total sample size n = 2702 (Lean-NAFLD: n = 493 vs overweight/obese-NAFLD: n = 2209)
Study nameModel Popul outcome Statistics for each study Difference in means and 95%CI
Fixed
random
Leung 2016 HB Fibrosis 0.400
–0.100
0.480
0.260
0.270
0.100
0.730
0.000
0.287
0.283
0.192
0.124
0.263
0.244
0.250
0.102
0.106
0.487
0.055
0.132
0.024 0.776 .037024165
.286678784
.419301290
.068156269
.280379721
.327751926
.000000000
1.000000000
.000000200
.032338661
0.143
0.996
0.738
0.760
0.300
0.938
0.955
0.395
0.542
–0.343
–0.036
–0.218
–0.220
–0.100
0.522
–0.955
0.179
0.024
Fibrosis
Fibrosis
Fibrosis
Fibrosis
Fibrosis
Fibrosis
Fibrosis
Difference
in means
Standard
error
Lower
limit
Upper
limit P-Value
Lean
–2.00 –1.00 0.00 1.00 2.00
Overweight/
obese
HB
HB
HB
HB
HB
HB
HB
Alam 2014
Kumar 2013
Akyuz 2015
Sookoian 2017
Y Honda 2016
A Fracanzani 2017
Margariti, 2013
F IGURE 1 Association analysis of liver fibrosis in lean-NAFLD patients versus overweight/obese - NAFLD patients. The effect indicates the
difference in means, which is the absolute difference between the mean value of fibrosis score [0-4], standard error, and the corresponding
lower and upper limits (95% confidence interval), according to the status of lean (non-obese) versus overweight/obese. The first author of the
study and the year of publication are shown under the sub-heading: “study name.” Popul: indicates design features (HB: hospital-based). In the
graph, the filled squares denote the effect of individual studies, and filled diamonds express combined fixed and random effects
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results of meta-regression must be taken with caution because the
number of studies5,16,18,19,21 included in the analysis of clinical co-
variables was small.
The presence of NASH in lean versus overweight/obese patients
with NAFLD was assessed based on information extracted from six
studies (n = 1679)5,17,18,20-22 that reported the proportion of
patients with diagnosis of NASH and non-NASH. We found that the
risk of having NASH (OR 0.58 95% CI 0.34-0.97) was significantly
lower in lean (n = 322) than in overweight/obese patients with
NAFLD (n = 1357) (P = .04, see Figure 2). While no publication bias
was noted (intercept 0.178, P = .92), we observed substantial and
significant heterogeneity (I2: 66.5, P = .01).
Sub-group analysis comparing Asian vs Caucasian showed that
the difference in the proportion of NASH patients in lean vs. over-
weight/obese remained significant among Caucasians (Figure S4).
Stratification according to ethnicity showed lack of intra-group
heterogeneity (Asian: I2: 54, P = .11 and Caucasian: I2: 24.7, P = .26).
Figure S5 shows the impact of each study on the combined pooled
effect.
Likewise, the analysis of NAFLD activity score (NAS) that was
based on results from eight studies5,16-22 showed that lean-NAFLD
patients have significantly lower mean score as compared to over-
weight/obese NAFLD patients (difference in means  SE:
0.58  0.16, P = .0004) (Figure 3); we found no publication bias (in-
tercept 0.68, P = .74).
We observed a significant heterogeneity (I2: 74.9, P = .0001) that
could not be explained by ethnicity (Asian: I2: 69, P = .021 and Cau-
casian: I2: 71.8, P = .014), Figure S6. Sub-group analysis within Asian
and Caucasian showed that the difference in the NAS score between
lean and overweight/obese patients was significant in both ethnic
groups.
The one-study-removed analysis (Figure S7) shows consistency
of the effect across the studies, and suggests a robust association
between the NAS score and the lean/ overweight-obese status.
Meta-regression analysis results suggested that HOMA-IR (slope:
0.42, P = .013), but not age (slope: 0.01, P = .8) or waist circumfer-
ence (slope: 0.14, P = .58) would explain the observed difference in
the NAS score, although this result should be interpreted with cau-
tion because there was limited information on clinical and biochemi-
cal co-variables to be incorporated into the analysis.
Finally, five studies (n = 1886)5,16,17,19,21 without evidence of
heterogeneity (I2: 46.5, P = .11) or publication bias (intercept 1.05,
P = .58) disclosed data of steatosis score according to lean and over-
weight/obese patients. The analysis showed that relative to over-
weight/obese NAFLD patients (n = 1562), lean-NAFLD (n = 324)
patients have significantly (P = .0023) lower steatosis scores (differ-
ence in means 0.23  0.07) (Figure 4).
4 | DISCUSSION
4.1 | Summary of main findings
Based upon the results yielded by the meta-analysis of eight studies,
which included data of histological outcomes in lean versus over-
weight/obese patients with NAFLD, we demonstrated that relative
to overweight/obese-NAFLD patients, lean patients have less severe
Lean vs overweight/obese patients with NAFLD: NASH
Study nameModel Popul outcome Statistics for each study Odds ratio and 95%CI
Total sample size n = 1679 (Lean-NAFLD: n = 322 vs overweight/obese-NAFLD: n = 1357)
Fixed
random
Leung 2016
Alam 2014
Kumar 2013
Sookoian 2017
A Fracanzani 2017
Margariti, 2013
HB NASH 0.673
1.304
0.395
0.663
0.306
0.455
0.561
0.583
0.395
0.710
0.128
0.293
0.192
0.100
0.428
0.348
1.148
2.395
1.222
1.500
0.488
2.067
0.737
0.977
NASH
NASH
NASH
NASH
NASH
HB
HB
HB
HB
HB
Odds
ratio
Lower
limit
Upper
limit
.145890515
.392710402
.107087507
.323738913
.000000628
.307503575
.000030970
.040337751
P-Value
Lean
0.2 0.5 1 2 5 100.1
Overweight/
obese
F IGURE 2 Association analysis of NASH in lean-NAFLD patients versus overweight/obese -NAFLD patients. The effect indicates OR (Odds
ratio) and the corresponding lower and upper limits (95% confidence interval), according to the status of lean (non-obese) and overweight/
obese. The first author of the study and the year of publication are shown under the sub-heading: “study name.” Popul: indicates design
features (HB: hospital-based). In the graph, the filled squares denote the effect of individual studies, and filled diamonds express combined
fixed and random effects
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histological disease. Specifically, we found that lean patients are less
likely to have NASH. While both groups of patients presented a sub-
stantial proportion of NASH (33% and 49% of lean and overweight/
obese-NAFLD patients, respectively, had NASH), the two groups
showed a different degree of histological scores. Consequently, the
disease progression in lean versus overweight/obese NAFLD could
not necessarily be identical. For instance, overweight/obese-NAFLD
patients tended to show a modest, but significant, increase in the
mean fibrosis score, as well as greater NAFLD activity and steatosis
scores when compared to lean-NAFLD patients. Furthermore, we
Lean vs overweight/obese patients with NAFLD: NAFLD Activity Score
Total sample size n = 2702 (Lean-NAFLD: n = 493 vs overweight/obese-NAFLD: n = 2209)
Study nameModel Popul outcome Statistics for each study Difference in means and 95%CI
Difference
in means
Standard
error
Lower
limit
Upper
limit P-Value
Fixed
random
Leung 2016
Alam 2014
Kumar 2013
Akyuz 2015
Sookoian 2017
Y Honda 2016
A Fracanzani 2017
Margariti, 2013
HB NAS 0.500 0.165
0.183
0.374
0.299
0.303
0.152
0.158
0.726
0.074
0.163
0.177
–0.359
0.068
–0.256
–0.255
0.402
0.890
–0.522
0.470
0.255
0.823 .002424486
1.000000000
.032246056
.269468519
.262414887
.000004099
.000000000
.214828801
.000000000
.000433579
0.359
1.532
0.916
0.935
0.998
1.510
2.322
0.761
0.895
0.000
0.800
0.330
0.340
0.700
1.200
0.900
0.616
0.575
NAS
NAS
NAS
NAS
NAS
NAS
NAS
HB
HB
HB
HB
HB
HB
HB
Lean
–4.00 –2.00 0.00 2.00 4.00
Overweight/
obese
F IGURE 3 Association analysis of NAFLD activity score (NAS) in lean-NAFLD patients versus overweight/obese -NAFLD patients. The
effect indicates the difference in means, which is the absolute difference between the mean value of NAS score, standard error, and the
corresponding lower and upper limits (95% confidence interval), according to the status of lean (non-obese) versus overweight/obese. The first
author of the study and the year of publication are shown under the sub-heading: “study name.” Popul: indicates design features (HB: hospital-
based). In the graph, the filled squares denote the effect of individual studies, and filled diamonds express combined fixed and random effects
Lean vs overweight/obese patients with NAFLD: Steatosis Score
Total sample size n = 1886 (Lean-NAFLD: n = 324 vs overweight/obese-NAFLD: n = 1562)
Study nameModel Popul outcome
Fixed
random
Leung 2016
Alam 2014
Akyuz 2015
Sookoian 2017
Y Honda 2016
HB Steatosis
Steatosis
Steatosis
Steatosis
Steatosis
HB
HB
HB
HB
Statistics for each study
Difference
in means
Standard
error
Lower
limit
Upper
limit P-Value
Difference in
means and 95%CI
Lean
–1.00 –0.50 0.00 0.50 1.00
Overweight/
obese
0.300 0.108 0.089
–0.220
–0.496
0.073
0.168
0.149
0.080
0.112
0.253
0.167
0.067
0.048
0.074
0.511 .005370043
1.000000000
1.000000000
.016557567
.000008582
.000000374
.002375655
0.220
0.496
0.727
0.432
0.337
0.370
0.000
0.000
0.400
0.300
0.243
0.225
F IGURE 4 Association analysis of steatosis score in lean-NAFLD patients versus overweight/obese -NAFLD patients. The effect indicates
the difference in means, which is the absolute difference between the mean value of steatosis score [0-3], standard error, and the
corresponding lower and upper limits (95% confidence interval), according to the status of lean (non-obese) versus overweight/obese. The first
author of the study and the year of publication are shown under the sub-heading: “study name.” Popul: indicates design features (HB: hospital-
based). In the graph, the filled squares denote the effect of individual studies, and filled diamonds express combined fixed and random effects
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observed a protective association between the lean status and the
risk of NASH (OR 0.58 95% CI 0.34-0.97), which was explored in a
sample of 1679 patients. A summary of the findings of our study is
shown in Figure 5.
4.2 | Limitations and strengths at study, outcome,
and review levels
Nevertheless, some limitations to our study should be noted, which
are implicit in the studies included in the meta-analysis. For instance,
it remains unclear whether the differences in the histological out-
comes between the two groups of patients can be explained by the
condition of being “lean” or “overweight/obese.” In fact, other co-
variables might have significantly influenced the severity of fibrosis
or NASH, including age, the presence of insulin resistance and/or
visceral adiposity. Unfortunately, limitations of the published studies
that failed to disclose data of HOMA-IR or waist circumference
according to lean and overweight/obese -NAFLD17,20,22 prevented
us from a proper meta-regression analysis to assess the potential
effect of modifiers’ or covariates. Even when considering these limi-
tations, it is worth noting that differences in HOMA-IR could
account for differences in the NAFLD activity score (NAS) between
the two groups which were consistent with previously reported clini-
cal-morphological correlations.23,24
While there was heterogeneity in the overall results, the effects
were homogeneous in the analysis stratified by ethnicity. In fact, the
observed difference in the fibrosis score and NASH proportion seems
to be restricted to the studies that included Caucasian population.
On the contrary, differences in the NAS score between lean and
non-lean could not be explained by sub-groping analysis of the stud-
ies according to ethnicity or other relevant characteristics.
It is unlikely that either the observed heterogeneity or the dif-
ferences according to ethnicity can be explained by methodologi-
cal diversity, which represent variability in study design, because
all the studies were hospital-based. Nevertheless, bias in the selec-
tion of patients cannot be ruled out as the reason/s of indicating
the liver biopsies were not necessarily homogeneous among the
studies (Table 1). Authors of some studies explained that liver
biopsy was indicated to patients who had either persistently ele-
vated levels of aminotransferases17 or abnormal liver test and /or
additional risk factors for NASH, including insulin resistance or
MetS,5,18 while in other studies, authors explained that regardless
of the biochemical profile, they conducted a liver biopsy on all
patents with NAFLD for the purpose of diagnosing and staging of
NASH.19,21 Furthermore, the observed heterogeneity and ethnic
differences might be both attributed to variability in the partici-
pants, which is known as clinical diversity. This source of variabil-
ity includes, but is not restricted to, dietary and environmental
factors, and genetic predisposition.19,21,25
A note of caution should be added because we included informa-
tion of histological outcomes in overweight and obese individuals as
a single category. Unfortunately, none of the studies but one
report20 provided data of overweight subjects as a separate group;
therefore, we were unable to estimate putative differences between
overweight and obese NAFLD-patients. As a remarkable aspect,
none of the studies included morbid obese patients, who are known
to present different histological features that would have introduced
bias in the analysis of overweight/obese group; Figure S8 shows
mean values of BMI (kg/m2) according to lean and non-lean study
participants.
Likewise, the lean group could have been sub-stratified into
underweight and normal weight8; in fact, these two sub-groups
Histological Disease Severity in lean-NAFLD vs overweight/Obese-NAFLD
n = 2209
n = 493
BMI ≤ 25
BMI > 25
Steatosis
score
0.22 ± 0.07
NAS
score
0.57 ± 0.16
Fibrosis
0.28 ± 0.13
NASH
1.7-fold
F IGURE 5 Histological disease severity
in lean versus overweight/obese NAFLD:
Being overweight/obese can raise the risk
of NASH by 1.7-fold. The image illustrates
the results yielded by the meta-analysis of
histological features of NAFLD in lean and
overweight/obese patients. Relative to
lean-NAFLD, overweight/obese NAFLD
patients tend to show a modest increase in
scores of histological outcomes associated
with the disease severity, including liver
fibrosis. The effect is indicated as the
difference in means  standard error
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could represent NAFLD patients in whom the disease would be
linked to different underlying mechanisms, for example malnutri-
tion/ malabsortion. Hence, the ideal study should contemplate at
least five different categories, including underweight, normal
weight, overweight, obese and morbid obese.8 Nevertheless, this
approach not only requires a special strategy for performing
inter-group comparisons (e.g., network meta-analysis) but should
guarantee an adequate sample size per group, which represents an
enormous challenge.
On the other hand, it can be argued that a BMI cut-off point for
defining overweight/ obese should not be >25 kg/m2 in individuals
from Asia, where a BMI cut-off of 23 kg/m2 is recommended.8
Unfortunately, all studies from Asia but the report of Kumar et al20
used a BMI < 25 kg/m2 to define lean subjects.
It should be also argued that NAFLD is not invariably associated
with the presence of features of the metabolic syndrome.26 The
study of Akyuz and coworkers showed that hemoglobin level is an
independent predictor of NASH severity not only in lean patients16
but also NAFLD patients without obesity and insulin resistance.26
Therefore, lean-NAFLD could represent a different clinical entity,
the pathogenesis of which could be mediated by other mechanisms,
for instance, microbial dysbiosis,27 extra-hepatic underlying
diseases,28 sarcopenia,29 or polycystic ovary syndrome with
hyperandrogenism.30
Finally, there were two studies for which the total sample
size (lean-NAFLD and overweight/obese NAFLD) was small
(fewer than 100 patients).20,22 Thus, it can be argued that small-
study-effects might have introduced bias into the pooled analysis.
Nevertheless, no publication bias was observed in any of the
assessed histological outcomes. Most importantly, we performed
“conservative” random-effects analysis, which assumes that the
effect sizes are heterogeneous and sampled from a distribution
of population effect sizes. In addition, the one-study-removed
analysis consistently demonstrated that the effect was in the
same direction in all the studies, including those studies that
might be regarded as underpowered (Figures S3, S5, and S7). For
instance, the difference in means of fibrosis score between lean
and overweight/obese patients with NAFLD was 0.25  0.14 and
0.29  0.13 in the study of Kumar20 and Margariti,22 respec-
tively, which is comparable to that of the observed pooled effect
(Figure 1).
The main strength of this study, however, stems from the rela-
tively large sample size that was subjected to the analyses (data from
2702 patients with NAFLD in whom the disease was characterised
by liver biopsy). Likewise, the magnitude and direction of the effects
of all the histological outcomes were consistently noted in both,
Asians and Caucasians. Interestingly, there was a remarkable unifor-
mity in the scoring system used for the histological assessment,
which was in all the studies the system developed by Kleiner et al14
Finally, rather than using the fixed-effect model, we calculated all
the effect sizes on the bases of the random-effect model, which
permit generalisations that extend beyond the studies included in a
systematic review.31
4.3 | Implications for clinical practice and future
research
The results of this meta-analysis suggested that overweight/obese
patients with NAFLD when compared to lean ones are ~ 1.71-fold
more likely to have NASH. This conclusion can be also expressed from
the perspective of being lean (nonobese), which reduces the occur-
rence of NASH by ~ 40% (OR: 0.58). In addition, overweight/obese
patients with NAFLD showed a significant increment of ~ 24.8% in the
mean of fibrosis score, and a modest increase of ~16.8% and 13.7% in
the mean of NAFLD activity and steatosis score, respectively, when
compared to lean-NAFLD. Taken together, the findings regarding liver
fibrosis could be of critical importance in the prognosis and long-term
clinical consequences of overweight/obese NAFLD patients. For
example, fibrosis stage, but not steatosis and lobular inflammation
grade, or NAS categories of the NAFLD score, have been previously
associated with liver and non-liver related- mortality.32-34 In addition,
fibrosis stage (from fibrosis F0 to F4) was independently associated
with liver-related mortality in a large longitudinal study of patients
with NAFLD, in which the difference in the fibrosis score imposed an
incremental score-dependent hazard-risk of negative outcomes (death
or liver transplantation) that escalated from 1.88 (F1) to 2.89 (F2) to
3.76 (F3) to 10.9 (F4) compared to stage F0.32 It is then reasonable to
speculate that an increment of ~25% in the mean of fibrosis score is
not negligible, but, rather, potentially imposing considerable long-term
impact on the natural history of the disease. Unfortunately, among the
studies included in our meta-analysis, there was only one remarkable
report from Hong-Kong in which the authors performed longitudinal
assessment of lean versus overweight/obese patients with NAFLD.21
In this study, Leung et al observed a higher frequency of clinical
events, including cardiovascular disease and death, in obese-NAFLD
than in lean-NAFLD.21
Therefore, whereas a greater risk of NASH and an increased
mean fibrosis score among overweight/obese patients are both
expected to have strong clinical impact, it should be highlighted that
the studies included in our meta-analysis provided us with cross-sec-
tional data. Hence, assessment of the long-term clinical conse-
quences of the histological outcomes in lean versus overweight/
obese patients should be guaranteed in further prospective studies.
Whether the presence of overweight/ obesity intrinsically predicts
the timing of referral to tertiary care then imposing differences in
the timing of NAFLD diagnosis is not known; future longitudinal
studies should also shed light on this issue.
In conclusion, the results of our cross-sectional study suggested
that overweight/obese and lean-NAFLD patients while sharing all the
risk factors of the MetS,5 show differences in the histological disease
severity. Overweight/obese NAFLD patients present a modest
increase of overall scores of histological outcomes, including liver
fibrosis, which could have substantial impact in the natural history of
the disease, not to mention that relative to normal weight, obesity —
regardless of whether it is associated with NAFLD— is, per se, associ-
ated with significantly higher all-cause mortality.35 This conclusion,
however, should not prevent physicians from the search of NASH or
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fibrosis in lean-NAFLD patients, particularly when presenting with
visceral obesity. Lean-NAFLD patients should also be considered as
potential candidates for treatment with novel therapeutic strategies
aimed to reverse NASH and/or liver fibrosis, because, as demon-
strated in this study, they may also present advanced disease.
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